Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Indocin, Indocin SR, tivorbex
Synonyms :
Class :
Non-steroidal anti-inflammatory drugs
Brand Name :
Indocin, Indocin SR, tivorbex
Synonyms :
Class :
Non-steroidal anti-inflammatory drugs
Dosage Forms & Strengths
Capsule-20mg,25mg,40mg,50mg
Capsule extended release-75mg
Powder for injection-1mg
Oral suspension-25mg/5ml
Suppository-50mg
Immediate release:
25 - 50
mg
Tablet
Orally
every 12 hrs
Do not exceed 200mg/day
Extended release-75-150mg/day orally in single dose or divided every 12 hours
Immediate release:
25 - 50
mg
Tablet
Orally
every 8 hrs
Extended release-75-150mg/day orally in single dose or divided every 12 hours
20
mg
Tablet
orally
3 times a day
40 mg orally twice a day
50
mg
Tablet
Orally
every 8 hrs
3 - 5
days
Nephrogenic Diabetes Insipidus
2
mg/kg
Tablet
Orally
every 8 hrs
Immediate release-25-50mg orally every 8-12 hours. Do not exceed 200mg/day
Extended release-75-150mg/day orally in a single dose or divided every 12 hours
Immediate release-25-50mg orally every 6-8hours.
Extended release-75-150mg/day orally in a single dose or divided every 12 hours
50mg orally every 8 hours for 3-5 days
Nephrogenic Diabetes Insipidus
2mg/kg/day orally every 8 hours
Immediate release-25-50mg orally every 8-12 hours. Do not exceed 200mg/day
Extended release-75-150mg/day orally in a single dose or divided every 12 hours
Immediate release-25-50mg orally every 6-8hours.
Extended release-75-150mg/day orally in a single dose or divided every 12 hours
Immediate release-25-50mg orally every 6-8hours.
Extended release-75-150mg/day orally in a single dose or divided every 12 hours
50mg orally every 8 hours for 3-5 days
Nephrogenic Diabetes Insipidus
2mg/kg/day orally every 8 hours
20mg orally thrice a day or 40 mg twice a day
Dosage Forms & Strengths
Capsule-25mg,50mg
Capsule extended release-75mg
Powder for injection-1mg
Oral suspension-25mg/5ml
Suppository-50mg
<2 years: safety and efficacy not established
2-14 years:1-2mg/kg/day orally every 6-12hours.Do not exceed 4mg/kg/day
>14 years:25-50 mg orally/per rectum every 8-12 hours
Indicated for nflammatory/rheumatoid disorders
:
<2 years: safety and efficacy not established
2-14 years:1-2mg/kg/day orally every 6-12hours.Do not exceed 4mg/kg/day
>14 years:25-50 mg orally/per rectum every 8-12 hours
Indicated for Inflammatory/rheumatoid disorders
:
<2 years: safety and efficacy not established
2-14 years:1-2mg/kg/day orally every 6-12hours.Do not exceed 4mg/kg/day
>14 years:25-50 mg orally/per rectum every 8-12 hours
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
when combined, may increase anticoagulation
when combined, may increase anticoagulation
when combined, may increase anticoagulation
when combined, may increase anticoagulation
when combined, may increase anticoagulation
may increase the risk or severity of hypertension when combined
when combined may increase anticoagulation
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may enhance the renal tubular clearance for anionic drug competition
neomycin/polymyxin B/bacitracin topical
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
increases the serum level of pemetrexed
increases the serum level of pralatrexate
it enhances the serum potassium levels
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
it enhances the serum potassium levels
when combined may increase anticoagulation
may diminish the effects of indomethacin by pharmacodynamic antagonism
it enhances the serum potassium levels
may increase the level of each other by an unknown mechanism
when combined may increase anticoagulation
when combined may increase anticoagulation
it enhances the serum potassium levels
may increase the level of each other by an unknown mechanism
may decrease the therapeutic effect when combined with glucagon and its analogs
may decrease the therapeutic effect when combined with glucagon and its analogs
may decrease the therapeutic effect when combined with glucagon and its analogs
may decrease the therapeutic effect when combined with glucagon and its analogs
Combining Indomethacin with pranlukast may cause a reduction in the Indomethacin’s metabolism
When indomethacin is used together with sertraline, the risk or seriousness of bleeding may be enhanced
When indomethacin is used together with ouabain, this leads to reduction in indomethacin excretion
When indomethacin is used together with bufexamac, this leads to enhanced risk or seriousness of adverse outcomes
indomethacin leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When indomethacin is used together with nifenazone, this leads to enhanced risk or seriousness of adverse events
When indomethacin is used together with adenine, this leads to a reduction in the indomethacin’s metabolism
May diminish the effects of indomethacin by pharmacodynamic antagonism
May diminish the effects of indomethacin by pharmacodynamic antagonism
bunazosin (Not available in the United States)
May diminish the effects of indomethacin by pharmacodynamic antagonism
May diminish the effects of indomethacin by pharmacodynamic antagonism
May diminish the effects of indomethacin by pharmacodynamic antagonism
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
When indomethacin is used together with diazoxide, this leads to reduction in therapeutic effectiveness of diazoxide
may have a decrease in excretion when combined with indomethacin
May enhances the effects of the other by pharmacodynamic synergism
may enhance the renal tubular clearance for anionic drug competition
may enhance the renal tubular clearance for anionic drug competition
may diminish the effects of indomethacin by pharmacodynamic antagonism
may enhance the renal tubular clearance for anionic drug competition
Frequency defined:
>10%
Renal insufficiency
Jaundice
Elevated liver function test values
1-10%
Dizziness
Dyspepsia
Epigastric pain
Indigestion
Nausea
Depression
Diarrhea
Fatigue
<1%
Angioedema
Aplastic anemia
Bone marrow depression
Congestive heart failure
Pulmonary edema
Thrombocytopenic purpura
Ulcerative stomatitis
Leukopenia
Macular and morbilliform eruptions
Post-marketing Reports
Pancreatitis
Pregnancy consideration: C
Lactation: The drug is excreted in the human breast milk
Pregnancy category:
Patient information leaflet
Generic Name: indomethacin
Pronounced: (in doe meth’ a sin)
Why do we use indomethacin?
Indomethacin is used to treat mild to moderate acute pain and relieves symptoms of gout and arthritis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
